PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are requir

Substitute for form 1449A/B/PTO

CA TRADENAR

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of 1 1

ed to respond to a conscision of information unless it contains a valid OMS control number.				
Complete If Known				
Application Number	10/751,601			
Filing Date	January 5, 2004			
First Named Inventor	Gérard Quentin			
Art Unit				
Examiner Name				
Attorney Docket Number	EGYP 3.9-030 CONT			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.'	Document Number Number-Kind Code ² (Finown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
						Г

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicants unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspip.nov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
FTP	CA	MOCK and XU, "Catalytic activity of carboxypeptidase B and of Carboxypeptidase Y with anisylazoformyl substrates," Bioorganic & Medicinal Chemistry Letters, Vol. 9, pgs 187-192 (1999)/		
FTP	СВ	MOCK et al., "Arazoformyl peptide surrogates as spectrophotometric kinetic assay substrates for carboxypeptidase A," Analytical Biochemistry, Vol. 239, pgs 218-222 (1996).		
FTP	CC	MOCK and STANFORD, "Arazoformyl dipeptide substrates for thermolysin. Confirmation of a reverse protonation catalytic mechanism," Biochemistry Vol 35 No. 23 pgs 7369-77 (1996).		
FTP	CD	SCHATTEMAN et al., "Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma," Clinical Chemistry Vol. 45, No. 6 pgs 807-13 (1999).	Ī	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<u> </u>	
Examiner /Fiona T. Powers/	Date Considered	02/12/2007

^{&#}x27;Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.